[Evaluation of efficacy and clinical impact of FDG-PET in patients with suspicion of recurrent colorectal cancer].
Borrego Dorado
I
I
Unidad de Diagnóstico de Medicina Nuclear, Hospitales Universitarios Virgen del Rocío, Sevilla. isabel.borrego.sspa@juntadeandalucia.es
Gómez Camarero
P
P
Ruiz Franco-Baux
J
J
Vázquez Albertino
R
R
D000230:Adenocarcinoma / Q000097:blood / Q000000981:diagnostic imaging* / Q000556:secondary* / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D019090:Case Management; D015179:Colorectal Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005188:False Negative Reactions; D005189:False Positive Reactions; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000556:secondary; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000556:secondary; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000000981:diagnostic imaging*; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
Evaluación de la eficacia y del impacto clínico de la PET-FDG en pacientes con sospecha de recurrencia de cáncer colorrectal.